Sex specific efficacy and safety outcomes in operable stage III non-small cell lung cancer (NSCLC): Pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14

被引：0
|
作者：
Frehner, L. [1 ]
Schaer, S. [2 ]
Hayoz, S. [2 ]
Guckenberger, M. [3 ]
Finazzi, T. [4 ]
Mark, M. T. [5 ]
Addeo, A. [6 ]
Mauti, L. A. [7 ]
Betticher, D. C. [8 ]
Stupp, R. [9 ]
Curioni-Fontecedro, A. [10 ]
Peters, S. [11 ]
Frueh, M. [12 ]
Rothschild, S. I. [13 ,14 ]
Pless, M.
Koenig, D. [15 ]
Schmitt-Opitz, I. [16 ]
Ris, H-B. [17 ]
Ozdemir, B. C. [1 ]
Schmid, S. [1 ]
机构：
[1] Univ Bern, Univ Hosp Bern, Inselspital, Dept Med Oncol, Bern, Switzerland
[2] Swiss Grp Clin Canc Res SAKK Competence Ctr, Stat, Bern, Switzerland
[3] Univ Zurich, Univ Zurich Hosp, Dept Radiat Oncol, Zurich, Switzerland
[4] Univ Hosp Basel, Clin Radiotherapy & Radiat Oncol, Basel, Switzerland
[5] Cantonal Hosp Graubuenden, Div Hematol Oncol, Chur, Switzerland
[6] Univ Hosp Geneva, Dept Oncol, Geneva, Switzerland
[7] Kantonsspital Winterthur, Dept Med Oncol, Winterthur, Switzerland
[8] Univ Fribourg, Cantonal Hosp Fribourg, Clin Oncol, Villars Sur Glane, Switzerland
[9] Northwestern Univ, Feinberg Sch Med, Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[10] Univ Fribourg, Cantonal Hosp Fribourg, Clin Oncol, Villar Sur Glane, Switzerland
[11] Ctr Hosp Univ Vaudois CHUV, Dept Oncol, Lausanne, Switzerland
[12] Kantonsspital St Gallen, Dept Med Oncol & Hematol, St Gallen, Switzerland
[13] Cantonal Hosp Baden, Ctr Oncol Hematol, Baden, Switzerland
[14] Cantonal Hosp Baden, Ctr Comprehens Canc, Baden, Switzerland
[15] Univ Hosp Basel, Dept Med Oncol, Basel, Switzerland
[16] Univ Zurich, Univ Zurich Hosp, Dept Thorac Surg, Zurich, Switzerland
[17] Hop Valais, Clin Thorac Surg, Sion, Switzerland
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1282
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1223P
引用
收藏
页码：S786 / S786
页数：1
相关论文
共 50 条
  • [21] Neutrophilia prior to neoadjuvant chemotherapy and neoadjuvant chemotherapy followed by immunotherapy with Durvalumb is a negative prognostic factor in patients with stage IIIA(N2) NSCLC - a post-hoc analysis of studies SAKK 16/00 and SAKK 16/14
    Rothschild, S.
    Holer, L.
    Savic, Prince S.
    Betticher, D.
    Fruh, M.
    Britschgi, C.
    Peters, S.
    Mark, M.
    Ochsenbein, A. F.
    Janthur, W. - D.
    Waibel, C.
    Mach, N.
    Froesch, P.
    Meisel, A.
    Stenner, F.
    Hayoz, S.
    Zippelius, A.
    Pless, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 206 - 206
  • [22] VP-16-213 - A PHASE-II STUDY OF NON-SMALL CELL LUNG-CANCER (NSCLC)
    ITRI, LM
    GRALLA, RJ
    KELSEN, DP
    CHAPMAN, RA
    GOLBEY, RB
    KAUFMAN, RJ
    YOUNG, CW
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 199 - 199
  • [23] PHASE-II TRIAL OF VP16-213 IN NON-SMALL CELL LUNG-CANCER (NSCLC)
    CHAPMAN, R
    ITRI, L
    GRALLA, R
    KELSEN, D
    CASPER, E
    GOLBEY, R
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1982, 7 (2-3) : 205 - 207
  • [24] AFT-16: Phase II trial of atezolizumab before and after definitive chemoradiation (CRT) for unresectable stage III non-small cell lung cancer (NSCLC).
    Ross, Helen J.
    Kozono, David E.
    Urbanic, James John
    Williams, Terence Marques
    Dufrane, Carter
    Bara, Ilze
    Gandhi, Mayank
    Schulze, Katja
    Brockman, JaneMichelle Michelle
    Wang, Xiaofei F.
    Gao, Junheng
    Vokes, Everett E.
    Stinchcombe, Tom
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] TREATMENT OF NON-SMALL CELL LUNG-CANCER WITH CISPLATIN, VP-16, AND MYTOMICIN
    ARRAZTOA, J
    ORLANDI, L
    RODRIGUEZ, R
    VOGEL, C
    RAMIREZ, G
    REVISTA MEDICA DE CHILE, 1987, 115 (01) : 31 - 36
  • [26] The clinical significance of CXCL16 in the treatment of advanced non-small cell lung cancer
    Shibata, Yuji
    Kobayashi, Nobuaki
    Sato, Takashi
    Nakashima, Kentaro
    Kaneko, Takeshi
    THORACIC CANCER, 2020, 11 (05) : 1258 - 1264
  • [27] Ramucirumab in the treatment of non-small cell lung cancer (vol 16, pg 637, 2017)
    Arrieta, Oscar
    Zatarain-Barron, Zyanya Lucia
    Cardona, Andres F.
    Carmona, Amir
    Lopez-Mejia, Mariana
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (05) : 645 - 645
  • [28] SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neo-adjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)
    Rothschild, S. I.
    Zippelius, A.
    Eboulet, E. I.
    Savic, S.
    Betticher, D.
    Bettini, A.
    Fruh, M.
    Jorger, M.
    Britschgi, C.
    Peters, S.
    Mark, M.
    Ochsenbein, A. F.
    Janthur, W. -D.
    Waibel, C.
    Mach, N.
    Gonzalez, M.
    Frosch, P.
    Goddar, G.
    Rusterholz, C.
    Pless, M.
    SWISS MEDICAL WEEKLY, 2020, : 3S - 3S
  • [29] Upregulation of amphiregulin on CD14++CD16-(classical) monocytes in non-small cell lung cancer.
    McCarthy, Fiona Margaret
    Candido, Juliana
    Rudd, Robin
    Steele, Jeremy P. C.
    Balkwill, Frances
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial
    Fruh, M.
    Ris, H. B.
    Xyrafas, A.
    Peters, S.
    Mirimanoff, R. O.
    Gautschi, O.
    Pless, M.
    Stupp, R.
    ANNALS OF ONCOLOGY, 2016, 27 (10) : 1971 - 1972
12345